↓ Skip to main content

A multiplex platform for the identification of ovarian cancer biomarkers

Overview of attention for article published in Clinical Proteomics, October 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A multiplex platform for the identification of ovarian cancer biomarkers
Published in
Clinical Proteomics, October 2017
DOI 10.1186/s12014-017-9169-6
Pubmed ID
Authors

Kristin L. M. Boylan, Kate Geschwind, Joseph S. Koopmeiners, Melissa A. Geller, Timothy K. Starr, Amy P. N. Skubitz

Abstract

Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients. We used a multiplex approach to identify protein biomarkers for detecting early stage ovarian cancer. This new technology (Proseek(®) Multiplex Oncology Plates) can simultaneously measure the expression of 92 proteins in serum based on a proximity extension assay. We analyzed serum samples from 81 women representing healthy, benign pathology, early, and advanced stage serous ovarian cancer patients. Principle component analysis and unsupervised hierarchical clustering separated patients into cancer versus non-cancer subgroups. Data from the Proseek(®) plate for CA125 levels exhibited a strong correlation with current clinical assays for CA125 (correlation coefficient of 0.89, 95% CI 0.83, 0.93). CA125 and HE4 were present at very low levels in healthy controls and benign cases, while higher levels were found in early stage cases, with highest levels found in the advanced stage cases. Overall, significant trends were observed for 38 of the 92 proteins (p < 0.001), many of which are novel candidate serum biomarkers for ovarian cancer. The area under the ROC curve (AUC) for CA125 was 0.98 and the AUC for HE4 was 0.85 when comparing early stage ovarian cancer versus healthy controls. In total, 23 proteins had an estimated AUC of 0.7 or greater. Using a naïve Bayes classifier that combined 12 proteins, we improved the sensitivity corresponding to 95% specificity from 93 to 95% when compared to CA125 alone. Although small, a 2% increase would have a significant effect on the number of women correctly identified when screening a large population. These data demonstrate that the Proseek(®) technology can replicate the results established by conventional clinical assays for known biomarkers, identify new candidate biomarkers, and improve the sensitivity and specificity of CA125 alone. Additional studies using a larger cohort of patients will allow for validation of these biomarkers and lead to the development of a screening tool for detecting early stage ovarian cancer in the general population.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 23%
Other 6 19%
Student > Ph. D. Student 5 16%
Student > Bachelor 5 16%
Student > Master 1 3%
Other 2 6%
Unknown 5 16%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 19%
Medicine and Dentistry 5 16%
Engineering 4 13%
Computer Science 3 10%
Agricultural and Biological Sciences 3 10%
Other 4 13%
Unknown 6 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2017.
All research outputs
#7,227,851
of 12,037,162 outputs
Outputs from Clinical Proteomics
#78
of 145 outputs
Outputs of similar age
#147,726
of 285,122 outputs
Outputs of similar age from Clinical Proteomics
#1
of 9 outputs
Altmetric has tracked 12,037,162 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 145 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,122 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them